Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...
A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...
A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...
In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...
Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse ...
A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...
Hormone therapy is commonly combined with radiation therapy for prostate cancer, but patients are often unsure how long it should be continued and why. A new study published in JAMA Oncology from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback